Goldman Sachs’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $245M | Sell |
|
|||||
|
2025
Q2 | $178M | Buy |
|
|||||
|
2025
Q1 | $114M | Buy |
|
|||||
|
2024
Q4 | $72.1M | Sell |
|
|||||
|
2024
Q3 | $97.9M | Sell |
|
|||||
|
2024
Q2 | $125M | Buy |
|
|||||
|
2024
Q1 | $38.9M | Sell |
|
|||||
|
2023
Q4 | $55.8M | Sell |
|
|||||
|
2023
Q3 | $55.3M | Buy |
|
|||||
|
2023
Q2 | $48.6M | Buy |
|
|||||
|
2023
Q1 | $46.1M | Sell |
|
|||||
|
2022
Q4 | $93.3M | Sell |
|
|||||
|
2022
Q3 | $93.1M | Sell |
|
|||||
|
2022
Q2 | $69.6M | Sell |
|
|||||
|
2022
Q1 | $111M | Sell |
|
|||||
|
2021
Q4 | $116M | Buy |
|
|||||
|
2021
Q3 | $126M | Sell |
|
|||||
|
2021
Q2 | $119M | Buy |
|
|||||
|
2021
Q1 | $98M | Sell |
|
|||||
|
2020
Q4 | $92.7M | Buy |
|
|||||
|
2020
Q3 | $85.5M | Sell |
|
|||||
|
2020
Q2 | $161M | Buy |
|
|||||
|
2020
Q1 | $84.9M | Sell |
|
|||||
|
2019
Q4 | $96.5M | Sell |
|
|||||
|
2019
Q3 | $92.3M | Buy |
|
|||||
|
2019
Q2 | $66.8M | Sell |
|
|||||
|
2019
Q1 | $95M | Sell |
|
|||||
|
2018
Q4 | $81.6M | Buy |
|
|||||
|
2018
Q3 | $82.3M | Buy |
|
|||||
|
2018
Q2 | $81.6M | Sell |
|
|||||
|
2018
Q1 | $120M | Sell |
|
|||||
|
2017
Q4 | $151M | Sell |
|
|||||
|
2017
Q3 | $211M | Buy |
|
|||||
|
2017
Q2 | $121M | Buy |
|
|||||
|
2017
Q1 | $70.9M | Buy |
|
|||||
|
2016
Q4 | $34.2M | Sell |
|
|||||
|
2016
Q3 | $63.9M | Buy |
|
|||||
|
2016
Q2 | $38.5M | Buy |
|
|||||
|
2016
Q1 | $40.3M | Buy |
|
|||||
|
2015
Q4 | $37M | Buy |
|
|||||
|
2015
Q3 | $26.2M | Sell |
|
|||||
|
2015
Q2 | $46.2M | Sell |
|
|||||
|
2015
Q1 | $62.1M | Buy |
|
|||||
|
2014
Q4 | $54M | Sell |
|
|||||
|
2014
Q3 | $44.6M | Buy |
|
|||||
|
2014
Q2 | $35.6M | Buy |
|
|||||
|
2014
Q1 | $34.4M | Buy |
|
|||||
|
2013
Q4 | $28.3M | Buy |
|
|||||
|
2013
Q3 | $22.3M | Sell |
|
|||||
|
2013
Q2 | $17.1M | Buy |
|